Why the study?
With the increasing use of immune checkpoint inhibitors, prompt recognition of reported multiorgan side effects is vital for their safe clinical use.
Does pembrolizumab cause concurrent Takotsubo cardiomyopathy, hypophysitis, and pneumonitis in patients with NSCLC?
Population
A 72-year-old female treated with pembrolizumab monotherapy for non-small cell lung cancer
Design
Case report
Authors
Loading...
May signal a rare ICI toxicity; leaves open confirmation of causality and incidence in larger cohorts.
Does pembrolizumab cause concurrent Takotsubo cardiomyopathy, hypophysitis, and pneumonitis in patients with NSCLC?
Pembrolizumab therapy can induce a severe, concurrent triad of Takotsubo cardiomyopathy, pneumonitis, and hypophysitis, highlighting the need for vigilance regarding multiorgan immune-related adverse events.
Khan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: